Piet Wigerinck

2.5k citations

44 papers · 1.8k indexed · h-index 19

Co-authors: Marie‐Pierre de Béthune Dominique Surleraux Piet Herdewijn Rudi Pauwels Sandra De Meyer Hilde Azijn Abdellah Tahri Celia A. Schiffer
Topics: HIV/AIDS drug development and treatment (19 papers)Synthesis and Characterization of Heterocyclic Compounds (12 papers)HIV Research and Treatment (10 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Journal of Biological Chemistry Cancer Research Journal of Virology
Partner nations: Belgium United States Sweden

In The Last Decade

Piet Wigerinck

44 papers receiving 1.7k citations

Peers

Countries citing papers authored by Piet Wigerinck

Since Specialization

Citations

This map shows the geographic impact of Piet Wigerinck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piet Wigerinck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piet Wigerinck more than expected).

Fields of papers citing papers by Piet Wigerinck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piet Wigerinck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piet Wigerinck. The network helps show where Piet Wigerinck may publish in the future.

Co-authorship network of co-authors of Piet Wigerinck

This figure shows the co-authorship network connecting the top 25 collaborators of Piet Wigerinck. A scholar is included among the top collaborators of Piet Wigerinck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piet Wigerinck. Piet Wigerinck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos 2020 ·Acta Clinica Belgica ·Patrick Durez,(unknown),T. Huizinga,(unknown),(unknown),Dirk Veelaert,Piet Wigerinck,René Westhovens	4
2	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial 2012 ·Annals of the Rheumatic Diseases ·René Westhovens,Filip De Keyser,(unknown),Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	18
3	Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects 2012 ·Drugs in R&D ·Florence Namour,Frédéric Vanhoutte,Johan Beetens,(unknown),(unknown),Piet Wigerinck	9
4	A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate 2011 ·Ghent University Academic Bibliography (Ghent University) ·René Westhovens,Filip De Keyser,(unknown),Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	1
5	Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study 2010 ·Cancer Research ·Giocondo Lorenzon,Lien Gheyle,Eva Vets,Florence Namour,Philippe Pujuguet,Philippe Clément-Lacroix,Piet Wigerinck,Frédéric Vanhoutte	3
6	In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor 2009 ·Antimicrobial Agents and Chemotherapy ·Tse‐I Lin,Oliver Lenz,Gregory Fanning,Thierry Verbinnen,Frédéric Delouvroy,Annick Scholliers,Katrien Vermeiren,Åsa Rosenquist,Michael Edlund,Bertil Samuelsson,Lotta Vrang,Herman de Kock,Piet Wigerinck,Pierre Raboisson,Kenneth Simmen	142
7	Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment 2009 ·European Journal of Pharmaceutics and Biopharmaceutics ·Lieven Baert,Gerben van ‘t Klooster,(unknown),(unknown),(unknown),(unknown),Koen Iterbeke,(unknown),Paul Stevens,Laurent Schueller,P. Van Remoortere,Guenter Kraus,Piet Wigerinck,Jan Rosier	185
8	Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Pierre Raboisson,Tse‐I Lin,Herman de Kock,Sandrine Vendeville,(unknown),David C. McGowan,Abdellah Tahri,Lili Hu,Oliver Lenz,Frédéric Delouvroy,Dominique Surleraux,Piet Wigerinck,Magnus Nilsson,Åsa Rosenquist,Bertil Samuelsson,Kenneth Simmen	18
9	Powder for reconstitution of the anti-HIV-1 drug TMC278 – Formulation development, stability and animal studies 2008 ·European Journal of Pharmaceutics and Biopharmaceutics ·Elke Van Gyseghem,(unknown),Lieven Baert,Jan Rosier,Gerben van ‘t Klooster,(unknown),Marie‐Paule Bouche,Laurent Schueller,P. Van Remoortere,Piet Wigerinck,Erwin Adams,Jos Hoogmartens,Guy Van den Mooter	15
10	Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121) 2008 ·Journal of Medicinal Chemistry ·Jean‐François Bonfanti,Christophe Meyer,(unknown),Jérôme Fortin,Philippe Müller,Laurence Quéguiner,Tom Gevers,(unknown),(unknown),Rudy Willebrords,Philip Timmerman,(unknown),P. Van Remoortere,Frans Janssens,Piet Wigerinck,Koen Andries	76
11	Dog model with implanted pump to test boosters for antiretroviral medication 2007 ·International Journal of Pharmaceutics ·Laurent Schueller,Lieven Baert,Sophie Lachau‐Durand,Herman Borghys,(unknown),Guy Van den Mooter,Elke Van Gyseghem,Tim H. M. Jonckers,P. Van Remoortere,Piet Wigerinck	2
12	Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action 2006 ·Journal of Virology ·Dirk Jochmans,Jérôme Deval,Bart Kesteleyn,Herwig Van Marck,(unknown),(unknown),Pascale Dehertogh,Tania Ivens,Marcia Van Ginderen,(unknown),Maryam Ehteshami,Piet Wigerinck,Matthias Götte,Kurt Hertogs	77
13	Relationship between structural properties and affinity for herpes simplex virus type 1 thymidine kinase of bromine substituted 5-heteroaromatic 2′-deoxyuridines 1996 ·Antiviral Research ·(unknown),(unknown),A. Olivier,G. Evrard,Arthur Van Aerschot,Piet Wigerinck,Piet Herdewijn,F. Durant	5
14	Stereoelectronic properties of five anti-HSV-1 2′-deoxynucleosides analogues with heterocyclic substituents in the 5-position: A comparison with BVDU 1994 ·Antiviral Research ·Anne Olivier,(unknown),Christine Evrard,G. Evrard,(unknown),Arthur Van Aerschot,Piet Wigerinck,Piet Herdewijn,F. Durant	8
15	Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogs 1993 ·Journal of Medicinal Chemistry ·Piet Wigerinck,(unknown),(unknown),Robert Snoeck,Prabhat C. Maudgal,Erik De Clercq,Piet Herdewijn	55
16	Synthesis and antiviral activity of 5-heteroaryl-substituted 2'-deoxyuridines 1991 ·Journal of Medicinal Chemistry ·Piet Wigerinck,Robert Snoeck,P. Claes,Erik De Clercq,Piet Herdewijn	41
17	Synthesis of 8‐Mercapto‐2′,3′‐Dideoxyadenosine and 8‐Mercapto‐2′,3′‐Dideoxyinosine 1991 ·Bulletin des Sociétés Chimiques Belges ·Piet Herdewijn,Arthur Van Aerschot,Piet Wigerinck,(unknown)	2
18	5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication 1991 ·Journal of Medicinal Chemistry ·Piet Wigerinck,Christophe Pannecouque,Robert Snoeck,P. Claes,Erik De Clercq,Piet Herdewijn	79
19	Synthesis and antiviral activity of 3'-heterocyclic substituted 3'-deoxythymidines 1990 ·Journal of Medicinal Chemistry ·Piet Wigerinck,Arthur Van Aerschot,G. Janssen,P. Claes,Jan Balzarini,Erik De Clercq,Piet Herdewijn	28
20	Sugar and Base-Modified 2',3'-Dideoxynucleosides as Potential Anti-Aids Drugs 1989 ·Nucleosides Nucleotides & Nucleic Acids ·Arthur Van Aerschot,Jan Balzarini,Rudi Pauwels,Piet Wigerinck,Erik De Clercq,Piet Herdewijn	1

About Piet Wigerinck

Piet Wigerinck is a scholar working on Virology, Infectious Diseases and Genetics, having authored 44 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (19 papers), Synthesis and Characterization of Heterocyclic Compounds (12 papers) and HIV Research and Treatment (10 papers). The work is most often cited by research in Virology (768 citations), Infectious Diseases (1.1k citations) and Hepatology (217 citations). Piet Wigerinck has collaborated with scholars based in Belgium, United States and Sweden. Frequent co-authors include Marie‐Pierre de Béthune, Dominique Surleraux, Piet Herdewijn, Rudi Pauwels, Sandra De Meyer, Hilde Azijn, Abdellah Tahri, Celia A. Schiffer, Nancy M. P. King and M. Prabu-Jeyabalan. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research and Journal of Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact